title: Design and Evaluation of Novel Antimicrobial and Anticancer Agents Among Tetrazolo[1,5-c]quinazoline-5-thione S-Derivatives.
abstract: The novel heterocyclization of 5-(2-aminophenyl)-1H-tetrazole with potassium ethylxanthogenate or carbon disulfide was proposed. The potassium salt of the tetrazolo[1,5-c]quinazoline-5-thione was subsequently modified by alkylation with proper halogen derivatives to (tetrazolo[1,5-c]quinazolin-5-ylthio)alkyls, N,N-dialkylethylamines, 1-aryl-2-ethanones, 1-(alkyl)aryl-2-ethanols, carboxylic acids, and esters. The structures of all newly synthesized compounds were confirmed by FT-IR, UV-vis, LC-MS, (1)H, (13)C NMR, and elemental analysis data. The substances were screened for antibacterial and antifungal activities (100 μg) against Escherichia coli, Staphylococcus aureus, Enterobacter aerogenes, Entrococcus faecalis, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Candida albicans. Preliminary bioluminescence inhibition tests against Photobacterium leiognathi Sh1 showed that substances 5.2-5.4, 6.1, 7.1 with ethanone or carboxylic acid substituents showed toxicity against bacteria cells. The substances chosen by the US National Cancer Institute (NCI) were screened for their ability to inhibit 60 different human tumor cell lines, where 2-(tetrazolo[1,5-c]quinazolin-5-ylthio)-1-(4-tolyl)ethanone (5.2), 3-(tetrazolo[1,5-c]quinazolin-5-ylthio)propanoic and related 3-metyl-butanoic acids (6.2, 6.3), and ethyl tetrazolo[1,5-c]quinazolin-5-ylthio)acetate (7.2) showed lethal antitumor activity (1.0 μM) against the acute lymphoblastic leukemia cell line (CCRF-CEM), and substances 5.2 and 6.3 exhibited moderate anticancer properties inhibiting growth of the leukemia MOLT-4 and HL06-(TB) cell lines. The moderate antitumor activity was demonstrated in 1-(2,5-dimethoxyphenyl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)ethanone (5.4) against the CNS cancer cell line SNB-75. Comparing the docking mode of the Gefitinib and synthesised substances on the ATP binding site of EGFR, it could be assumed that these compounds might act in the same way. The results of the investigation could be considered as a useful base for future development of potent antimicrobials and antitumor agents among tetrazolo[1,5-c]quinazoline-5-thione S-derivatives.
authors: Department of Pharmaceutical Chemistry, Zaporizhzhya State Medical University, Mayakovsky 26 ave., 69035, Zaporizhzhya, Ukraine.
authors: Lyudmyla M
authors: LM
authors: Antypenko
authors: Sergey I
authors: SI
authors: Kovalenko
authors: Olexii M
authors: OM
authors: Antypenko
authors: Andrey M
authors: AM
authors: Katsev
authors: Olena M
authors: OM
authors: Achkasova
keywords: 5-R-tetrazolo[1,5-c]quinazoline-5-thiones; Antibacterial; Anticancer; Antifungal; Bioluminescence
references: Cancer Res. 2002 Oct 15;62(20):5749-54
references: 12384534
references: Cancer Res. 2006 Feb 1;66(3):1630-9
references: 16452222
references: Cancer Res. 2002 Dec 15;62(24):7284-90
references: 12499271
references: Cancer Res. 1997 Nov 1;57(21):4838-48
references: 9354447
references: Bioorg Med Chem. 2009 Mar 15;17(6):2410-22
references: 19251421
references: Nat Biotechnol. 2008 Jan;26(1):127-32
references: 18183025
references: Eur J Med Chem. 2004 Jun;39(6):499-505
references: 15183908
references: Prog Med Chem. 1980;17:151-83
references: 7031768
references: J Med Chem. 2000 Jan 13;43(1):133-8
references: 10633045
references: Cancer Res. 2006 Dec 1;66(23):11409-15
references: 17145887
references: J Med Chem. 2006 Nov 2;49(22):6465-88
references: 17064066
references: Mol Cancer Ther. 2001 Dec;1(2):85-94
references: 12467226
references: Chem Pharm Bull (Tokyo). 2009 Jun;57(6):580-5
references: 19483337
references: Arch Pharm (Weinheim). 2009 Nov;342(11):651-62
references: 19882690
references: Toxicol In Vitro. 2003 Aug;17(4):457-63
references: 12849729